-
Mashup Score: 5Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas - 10 month(s) ago
We identified CD20 loss at progression in the phase 1/2 GO29781 trial of mosunetuzumab monotherapy in B-cell NHL.Reduced transcription or gain of truncating mut
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 103How I Treat Post-Transplant Lymphoproliferative Disorder - 1 year(s) ago
Post-transplant lymphoproliferative disorder (PTLD) is an important and potentially life-threatening complication of solid organ transplant (SOT) and hematopoie
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6How I Treat Post-Transplant Lymphoproliferative Disorder - 1 year(s) ago
Post-transplant lymphoproliferative disorder (PTLD) is an important and potentially life-threatening complication of solid organ transplant (SOT) and hematopoie
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1GDU HEM 2023 - 2 year(s) ago
Herbert Irving Assistant Professor of MedicineColumbia UniversityNew York, New YorkMy research goals are focused on developing targeted therapies for the treatment of lymphoma. As a physician-scientist, I aim to directly translate observations and concepts developed in the laboratory to patient care and back again to the laboratory. I have over 10 years of experience in directing laboratory…
Source: www.eventscribe.netCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma - 2 year(s) ago
Key Points. Chemo-free biologic combination of romidepsin and lenalidomide is feasible and effective as initial therapy for PTCLRomidepsin and lenalidomide comb
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Role of Stem Cell Transplant in CD30-positive PTCL following Frontline Brentuximab Vedotin+CHP or CHOP in ECHELON-2 - 3 year(s) ago
Key Points. Consolidative SCT should be considered in patients with CD30-positive PTCL in a CR following frontline A+CHP treatmentFurther studies are needed to
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Ferentino "Città d'Arte, Storia, Cultura, Tradizione" - 4 year(s) ago
Realizzato dal Comune di Ferentino e dalla Pro Loco di Ferentino.Prodotto dalla Creativeroom di Giorgio Capaci.La regia è firmata da Saria Cipollitti, la dir…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Falchi and colleagues report on a potential future treatment for patients with peripheral T-cell lymphoma (PTCL) that targets the widespread epigenetic dysregul
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 8The role of PET in first-line treatment of Hodgkin lymphoma - 4 year(s) ago
PET using 18F-fluorodeoxyglucose is central to the management of patients with Hodgkin lymphoma, and PET-adapted strategies have facilitated major improvements in overall survival. Although unmet needs include addressing fertility preservation, cardiovascular health, and survivorship issues, along with a need for better cure rates in the older patient, the improved survival of most patients with…
Source: The Lancet HaematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Milestones in cancer - 4 year(s) ago
Cancer milestones main content …
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
RT @hjcherng: Fun commentary we wrote on CD20 loss after bispecific antibodies in response to Schuster et al (https://t.co/fSSZ3RomOg), see…